Adinazolam

Adinazolam

200px
200px
Systematic (IUPAC) name
1-(8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,5-a] [1,4]benzodiazepin-1-yl)-N,N-dimethylmethanamine
Clinical data
Pregnancy category	?
Routes of administration	Oral
Legal status
Legal status	Schedule IV(US)
Pharmacokinetic data
Bioavailability	?
Metabolism	Hepatic
Biological half-life	< 3 hours
Excretion	Renal
Identifiers
CAS Number	37115-32-5
ATC code	N05BA07 (WHO)
PubChem	CID 37632
DrugBank	APRD00724
ChemSpider	34519
Chemical data
Formula	C19H18ClN5
Molar mass	351.8[[]]
(verify)

Adinazolam (marketed under the brand name Deracyn) is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative, and antidepressant properties. Adinazolam was developed by Dr. Jackson B. Hester, who was seeking to enhance the antidepressant properties of alprazolam, which he also developed.

Indications

Adinazolam is indicated as a treatment for anxiety and status epilepticus.

Pharmacology

Adinazolam produces inhibitory effects by binding to GABA receptors. This increases the effects of GABA.

Metabolism

Adinazolam was reported to have active metabolites in the August 1984 issue of The Journal of Pharmacy and Pharmacology. The main metabolite is N-desmethyladinazolam. The other two metabolites are alpha-hydroxyalprazolam and estazolam. In the August 1986 issue of that same journal, Sethy, Francis and Day reported that proadifen inhibited the formation of N-desmethyladinazolam.

Chemistry

500px

Hester, J. B.; Rudzik, A. D.; Von Voigtlander, P. F.; J. Med. Chem. 1980, 23, 392.

http://dx.doi.org/10.1021/jm00178a009

See also

• Benzodiazepine